Arvinas and Pfizer Announce Phase 3 Trial Results

Arvinas Holding Company ( (ARVN) ) just unveiled an announcement.

On May 31, 2025, Arvinas, Inc. and Pfizer announced detailed results from their Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant as a monotherapy for ER+/HER2- advanced or metastatic breast cancer. The trial demonstrated a significant improvement in progression-free survival among patients with ESR1 mutations, with vepdegestrant reducing the risk of disease progression or death by 43% compared to fulvestrant. Despite not reaching statistical significance in the intent-to-treat population, the results suggest vepdegestrant’s potential as a best-in-class treatment option. The companies plan to submit a New Drug Application to the FDA in the latter half of 2025, indicating a significant step towards regulatory approval and potential market introduction.

The most recent analyst rating on (ARVN) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.

Spark’s Take on ARVN Stock

According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.

Arvinas Holding Company has shown strong revenue growth and promising pipeline advancements, particularly in oncology and neurology. However, challenges in profitability, cash flow, and bearish technical indicators weigh heavily on the stock. Strategic initiatives and positive clinical data provide optimism, but the stock remains speculative.

To see Spark’s full report on ARVN stock, click here.

More about Arvinas Holding Company

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer. The company is known for its innovative approach using PROteolysis TArgeting Chimeras (PROTACs) to degrade disease-causing proteins, with a particular focus on breast cancer treatments.

Average Trading Volume: 3,013,094

Technical Sentiment Signal: Sell

Current Market Cap: $525.5M

See more data about ARVN stock on TipRanks’ Stock Analysis page.